Holen Sie sich die Stockscreener-App
7.055
2.68%
-0.225
Wave Life Sciences Ltd Aktie (WVE) Neueste Nachrichten
A Look At Wave Life Sciences (WVE) Valuation After INLIGHT Phase 1 Obesity Data Disappoints Investors - simplywall.st
Wave Life Sciences (WVE) Is Up 14.4% After Phase 1 Data On Long‑Acting Obesity Drug WVE‑007 - simplywall.st
Wave Life Sciences Ltd. (WVE) stock price, news, quote and history - Yahoo Finance Singapore
WVE.O PE Ratio & Valuation, Is WVE.O Overvalued - Intellectia AI
Gold Royalty, Wave Life Sciences, and More Stocks See Action From Activist Investors -- Barrons.com - moomoo.com
Wave Life Sciences Ltd. (WVE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wave Life Sciences plunges after early-stage data for obesity therapy - MSN
Wave Life Sciences Ltd. (WVE) PT increased to $52 at Canaccord following pipeline review - MSN
WVE.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
WVE.O Technical Analysis & Stock Price Forecast - Intellectia AI
Wave Life Sciences’ Weight Loss Drug Phase 1 Clinical Data Triggers Stock Volatility, Yet Differentiated Path Still Shows Promise - NAI500
Wave Life Sciences (WVE) Surges 9.5%: Is This an Indication of Further Gains? - qz.com
Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007 - Investing News Network
Wells Fargo Maintains Wave Life Sciences(WVE.US) With Buy Rating, Cuts Target Price to $13 - Moomoo
WVE Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
JPMorgan Chase & Co. Has $6.30 Million Position in WAVE Life Sciences Ltd. $WVE - MarketBeat
WVE posts interim data from phase I study on WVE-007, stock tanks - MSN
WAVE Life Sciences (NASDAQ:WVE) Shares Gap UpTime to Buy? - MarketBeat
Wave Life Sciences Stock (WVE) Opinions on INLIGHT Trial Data - Moomoo
Wave Life Sciences Obesity Data Highlights Visceral Fat Focus Over Weight Loss - Yahoo Finance
[SCHEDULE 13D/A] Wave Life Sciences Ltd. Amended Major Shareholder Report - Stock Titan
RA Capital boosts Wave Life Sciences (NASDAQ: WVE) stake with 8.8M-share open-market buy - Stock Titan
Wave Life Sciences Ltd. (WVE) PT Increased to $52 at Canaccord Following Pipeline Review - Insider Monkey
WaVe Life Sciences Ltd (WVE) Stock Price Quote Today & Current Price Chart - Capital.com
Why is Wave Life Sciences stock falling after weight loss study data? - MSN
13 Best Stocks to Invest In on Robinhood for Beginners - Insider Monkey
Wave Life Sciences shares plunge 30% despite encouraging obesity trial results - msn.com
WVE Should I Buy - Intellectia AI
Wave hits 52-week low as analysts react to obesity drug data - msn.com
ARWR Stock Slid Lower Today — What Does Wave Life Sciences Have To Do With It? - Stocktwits
Can Wave Life Sciences’ (WVE) Visceral Fat Data Redefine Its Obesity Strategy Despite Modest Weight Loss? - simplywall.st
WAVE Life Sciences (NASDAQ:WVE) Stock Price Up 5.9%Time to Buy? - MarketBeat
Assessing Wave Life Sciences (WVE) Valuation After Volatile Reaction To WVE-007 Phase 1 Results - simplywall.st
Setback to Wave Life Sciences: Obesity Drug WVE-007 Shows Limited Efficacy in Early Trial - Medical Dialogues
Chances Slimmer For Wave’s WVE-007 After Lower BMI Patients Fail To Shift Weight - Citeline News & Insights
WVE Shares Preliminary Results from Phase I Trial of WVE-007, Stock Plummets - Bitget
INHBE inhibitions? Data from Wave send ripples - BioWorld MedTech
Wave Life Sciences Crashes Deep into Oversold Territory as Obesity Drug Data Disappoints. Should You Buy the Dip? - Barchart.com
WVE Posts Interim Data From Phase I Study on WVE-007, Stock Tanks - finance.yahoo.com
Bank of America Has Lowered Expectations for WAVE Life Sciences (NASDAQ:WVE) Stock Price - MarketBeat
Wave Life Sciences Slips as Obesity Data Fails to Convince - Yahoo Finance
Wells Fargo & Company Cuts WAVE Life Sciences (NASDAQ:WVE) Price Target to $13.00 - MarketBeat
A Quick Look at Today's Ratings for Wave Life Sciences(WVE.US), With a Forecast Between $13 to $39 - Moomoo
Wave Life Sciences stock hits 52-week low at $5.27 By Investing.com - Investing.com Australia
Wedbush Cuts Price Target on Wave Life Sciences to $15 From $35, Keeps Outperform Rating - MarketScreener
RBC Capital reiterates Wave Life Sciences stock rating on obesity data - Investing.com India
Risk-Adjusted Buy Rating on Wave Life Sciences: Differentiated Obesity Mechanism, Reset Valuation, and Long-Term Upside Despite 400 mg Uncertainty - TipRanks
Wave Life Sciences (WVE) Plummets 30% Following INLIGHT Obesity Trial Results - MEXC
Wave loses half its market cap on obesity data - biocentury.com
WAVE Life Sciences Shares Phase 1 WVE-007 Data Showing Visceral Fat Loss, Muscle Preservation Signal - MarketBeat
Wave Life Sciences Reports Positive Phase 1 Results for WVE-007 in Obesity, Showing Significant Visceral Fat Reduction and Muscle Preservation at 6 Months 123 - Minichart
Small U.S. Stocks Decrease; WAVE Life Sciences Takes Biggest Hit - Moomoo
Stock Market Today, March 26: Wave Life Sciences Plunges After High Dose Obesity Drug Data Disappoints - The Globe and Mail
Wave Life Sciences Ltd. (WVE) Discusses Positive Interim Phase I Data from INLIGHT Trial of WVE-007 for ObesitySlideshow (NASDAQ:WVE) 2026-03-26 - Seeking Alpha
Clear Street lowers Wave Life Sciences stock price target on obesity market outlook - Investing.com
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):